Anna’s paper on the effectiveness of several current antivirals against both lab and UK clinical isolates of human parainfluenza type 3 (PIV3) is now accepted for publication. The study identified favipiravir as a potentially useful therapeutic agent against PIV3, and also showed significant differences in the susceptabilities of lab-adapted and recent UK clinical strains of PIV3 to the neuraminidase inhibitor zanamavir.